Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR p.L858R status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.